Evidence map›Paper›PMID 39514166›Full record

ArticleMolecular diagnosis & therapy2025

Extracellular Histones Profiles of Pediatric H3K27-Altered Diffuse Midline Glioma.

Diana Buzova, Lucia Lisa Petrilli, Jan Frohlich, Desislava K Tsoneva, Salvatore Daniele Bianco, Maria Rita Braghini, Anna Alisi, Angela Mastronuzzi, Jan Cerveny, Tommaso Mazza and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular diagnosis & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Diana Buzova *Department of Adaptive Biotechnologies, Global Change Research Institute CAS, Brno, Czech Republic.
Lucia Lisa Petrilli *Research Unit of Genetics and Epigenetics of Pediatric Cancer, Bambino Gesù Children's Hospital-IRCCS, Rome, Italy.
Jan Frohlich *International Clinical Research Center, St Anne's University Hospital, Brno, Czech Republic.
Desislava K Tsoneva *Department of Medical Genetics, Medical University of Varna, Varna, Bulgaria.
Salvatore Daniele Bianco *Bioinformatics Laboratory, Fondazione IRCCS Casa Sollievo della Sofferenza, S. Giovanni Rotondo, (FG), Italy.
Maria Rita BraghiniResearch Unit of Genetics of Complex Phenotypes, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Anna AlisiResearch Unit of Genetics of Complex Phenotypes, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Angela MastronuzziNeuro-Oncology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Jan CervenyDepartment of Adaptive Biotechnologies, Global Change Research Institute CAS, Brno, Czech Republic.
Tommaso MazzaDepartment of Medical Genetics, Medical University of Varna, Varna, Bulgaria.
Maria VinciResearch Unit of Genetics and Epigenetics of Pediatric Cancer, Bambino Gesù Children's Hospital-IRCCS, Rome, Italy.
Manlio VinciguerraDepartment of Stem Cell Biology and Transplantology, Research Institute of the Medical University of Varna, Varna, Bulgaria. manlio.vinciguerra@mu-varna.bg.ORCID 0000-0002-1768-3894

Funding

Ministerstvo Zdravotnictví Ceské Republiky NU23-03-00318Ministry of Education and Science #KP-06-DV/4
6 · The paper itself

Abstract

backgroundDiffuse midline glioma, H3 K27-altered (DMG) is a fatal tumour that arises in the midline structures of the brain. When located in the pons, it is more commonly referred to as diffuse intrinsic pontine glioma (DIPG). DMG/DIPG is usually diagnosed when children are < 10 years, and it has a median overall survival of < 12 months after diagnosis. Radiological imaging is still the gold standard for DIPG diagnosis while the use of biopsy procedures led to our knowledge on its biology, such as with the identification of the canonical histone H3K27M mutation. However, the need to improve survival encourages the development of non-invasive, fast and inexpensive assays on biofluids for optimizing molecular diagnoses in DMG/DIPG. Here, we propose a rapid, new, imaging and epigenetics-based approach to diagnose DMG/DIPG in the plasma of paediatric patients.

methodsA total of 20 healthy children (mean age: 10.5 years) and 24 children diagnosed with DMG/DIPG (mean age: 8.5 years) were recruited. Individual histones (H2A, H2B, H3, H4, macroH2A1.1 and macroH2A1.2), histone dimers and nucleosomes were assayed in biofluids by means of a new advanced flow cytometry ImageStream(X)-adapted method.

resultsWe report a significant increase in circulating histone dimers and tetramers (macroH2A1.1/H2B versus control: p value < 0.0001; macroH2A1.2/H2B versus control: p value < 0.0001; H2A/H2B versus control: p value < 0.0001; H3/H4 versus control: p value = 0.008; H2A/H2B/H3/H4 versus control: p value < 0.0001) and a significant downregulation of individual histones (H2B versus control: p value < 0.0001; H3 versus control: p value < 0.0001; H4 versus control: p value < 0.0001). Moreover, histones were also detectable in the cerebrospinal fluid (CSF) of patients with DMG/DIPG and in the supernatant of SF8628, OPBG-DIPG002 and OPBG-DIPG004 DMG/DIPG cell lines, with patterns mostly similar to each other, but distinct compared to blood plasma.

conclusionsIn summary, we identified circulating histone signatures able to detect the presence of DMG/DIPG in biofluids of children, using a rapid and non-invasive ImageStream(X)-based imaging technology, which may improve diagnosis and benefit the patients.

Indexed as

Brain Stem NeoplasmsDiffuse Intrinsic Pontine GliomaGliomaHistonesAdolescentBiomarkers, TumorChildChild, PreschoolFemaleHumansMaleMutationNucleosomesBiomarkers, TumorHistonesNucleosomes

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.